Shigella News and Research

RSS

T3SS-dependent bacteria may be a suitable point of attack for future antibiotics: Study

So-called type-3 secretion systems of pathogenic bacteria may be a suitable point of attack for future antibiotics. This is shown by Professor Maria Fällman and her associates at Umeå University in Sweden in the Proceeding of the National Academy of Sciences, PNAS, in the US.

18 Jan 2011

VBI researchers receive grant to study immune responses to gut pathogens

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded a $10.6 million grant to researchers at the Virginia Bioinformatics Institute (VBI) and collaborators to determine how the human immune system responds to infection by pathogens of the gut. The funding will be used to apply mathematical modeling to the study of immune responses to gut pathogens.

11 Oct 2010

Phase I study of Shigella dysenteriae bioconjugate vaccine meets primary, secondary endpoints

GlycoVaxyn AG, a leader in the development of innovative vaccines, announced today that the Phase I study of its Shigella dysenteriae bioconjugate vaccine has been completed and met the primary and secondary endpoints: demonstration of safety and immunogenicity.

8 Oct 2010

Mucosis collaborates with PATH to pursue use of Mimopath technology in diarrhea vaccines

Dutch biotechnology company Mucosis B.V. announced today that it has entered into a collaboration agreement with the global health nonprofit organization PATH to pursue the use of the company's Mimopath technology in oral vaccines to prevent and treat severe diarrhea.

28 Sep 2010

PolyMedix presents defensin mimetic antibiotics data at ICAAC Conference

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, today presented five posters at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

16 Sep 2010

NIH awards $3.4M grant for preclinical development of novel Staphylococcus aureus vaccine

GlycoVaxyn AG, a leader in the development of innovative bioconjugate vaccines, and Professor Jean Lee, principal investigator at the Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, announced today that they have received a USD 3.4 million NIH grant to finance preclinical development of a novel Staphylococcus aureus vaccine. S. aureus is a major cause of hospital-based infections.

4 May 2010

Breast-feeding may help lower risk of death from Shigella infection in developing countries: Study

Teaching parents about the importance of continued breast-feeding may help to lower the risk of death from brain disease (encephalopathy) related to Shigella infection in developing countries, reports a study in the May issue of The Pediatric Infectious Disease Journal.

4 May 2010

Combination of antibiotics can cure Chlamydia-induced ReA: Study

Researchers from University of South Florida College of Medicine found a combination of antibiotics to be an effective treatment for Chlamydia-induced reactive arthritis, a major step forward in the management, and possibly cure, of this disease. Results of this study are published in the May issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.

29 Apr 2010

Escherichia coli cases drop in 2009

As per a report from the Centers for Disease Control and Prevention (CDC) a 12 % drop in rates of Escherichia coli (E.coli) infection has been noted in 2009 as compared to statistics for 2008. This is being seen by federal health officials as a sign that the new food safety measures are effective. Most of the pathogens under study are from the bacteria family like E.coli 0157, salmonella, campylobacter, listeria and vibrio. It was found that food poisoning rates for the most common pathogens have changed little from statistics collected in 2004.

16 Apr 2010

VA may expand list of Gulf War illnesses

The Army Times/Veterans Today: "In a boost for veterans of the 1991 Persian Gulf War and those who have served in recent years in Iraq and Afghanistan, the Veterans Affairs Department has proposed changes to its list of illnesses that are presumed connected to service to include nine infectious diseases."

1 Apr 2010

GlycoVaxyn initiates Phase I clinical study of GVXN SD133 vaccine candidate against Shigella dysenteriae

GlycoVaxyn, a pioneer in the development of innovative bioconjugate vaccines, has commenced a Phase I clinical study with its vaccine candidate (GVXN SD133) against Shigella dysenteriae, a cause of serious intestinal infections. This is the first product from the company to enter clinical evaluation.

23 Feb 2010

Eating reptile meat can cause varying degrees of illness

Reptiles are bred in captivity primarily for their skins, but some restaurants and population groups also want them for their meat. A study shows that eating these animals can have side effects that call into question the wisdom of eating this 'delicacy.'

10 Feb 2010

"Make Our Food Safe" coalition urges Senate to enact stronger food safety laws

Over the next several weeks, the U. S. Senate has an historic opportunity to take a major step toward improving food safety for all Americans. That is why a coalition of public health professionals, consumer organizations and groups representing victims of foodborne illness is sending the message that it is time to "Make Our Food Safe for the Holidays!"

13 Nov 2009

U.S. army Phase I STTR contract for Intralytix

Intralytix, Inc. announced today that it has received a U.S. Army Phase I STTR contract supporting the development of a bacteriophage-based probiotic preparation for managing Shigella infections.

9 Oct 2009

E. coli pervasive in stream-water with fecal indicator bacteria

Bacteria commonly used to indicate health risks in recreational waters might not be so reliable after all. Pathogenic E. coli were pervasive in stream-water samples with low concentrations of fecal indicator bacteria.

23 Sep 2009

Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella

Ceragenix Pharmaceuticals, Inc. (“Ceragenix”) (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that the National Institutes of Health (“NIH”) has awarded a $2.87 million grant to fund the pre clinical development of a Ceragenin™based oral drug to treat two common and potentially deadly gastrointestinal infections: Clostrdium difficile and Shigella.

9 Sep 2009

J. Craig Venter Institute offers new Affymetrix array for faster identification of E. coli and shigella

Affymetrix, Inc. and the National Institute of Allergy and Infectious Diseases (NIAID)-supported Pathogen Functional Genomics Resource Center (PFGRC) at the J. Craig Venter Institute (JCVI) today announced the launch of the Affymetrix FDA-ECSG custom microarray for identifying and discriminating between different strains of E. coli and Shigella.

6 Aug 2009

New understanding of 3D structure of bacterial secretion proteins

New details of the composition and structure of a needlelike protein complex on the surface of certain bacteria may help scientists develop new strategies to thwart infection.

26 Apr 2009

Key genetic mechanism a potential key to new class of antibiotics

Researchers have determined the structure of a key genetic mechanism at work in bacteria, including some that are deadly to humans, in an important step toward the design of a new class of antibiotics, according to an accelerated publication that appeared online today as a "paper of the week" in the Journal of Biological Chemistry.

20 Apr 2009

CDC reports progress in foodborne illness prevention has reached a plateau

The incidence of the most common foodborne illnesses has changed very little over the past three years, according to a 10-state report released Thursday by the Centers for Disease Control and Prevention.

12 Apr 2009